Patent trend and competitive analysis of cancer immunotherapy in the United States

References

• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med. 2016;14:73. doi:10.1186/s12916-016-0623-5. PMID:27151159.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, et al. Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016;4:15. doi:10.1186/s40425-016-0118-0. PMID:26981245.
   PubMed Web of Science ®Google Scholar
• Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014;33:434–44. doi:10.5732/cjc.014.10122. PMID:25189716.
   PubMed Web of Science ®Google Scholar
• Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL. Cancer immunotherapy trials: Leading a paradigm shift in drug development. J Immunother Cancer. 2016;4:42. doi:10.1186/s40425-016-0146-9. PMID:27437105.
   PubMed Web of Science ®Google Scholar
• Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15:457–72. doi:10.1038/nrc3973. PMID:26205340.
   PubMed Web of Science ®Google Scholar
• Gedye C, van der Westhuizen A. & John T. Checkpoint immunotherapy for cancer: Superior survival, unaccustomed toxicities. Intern Med J. 2015;45:696–701. doi:10.1111/imj.12653. PMID:25444021.
   PubMed Web of Science ®Google Scholar
• Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology. 2015;145:182–201. doi:10.1111/imm.12459. PMID:25826229.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33:1974–82. doi:10.1200/JCO.2014.59.4358. PMID:25605845.
   PubMed Web of Science ®Google Scholar
• Blumenthal GM, Pazdur R. Approvals in 2016: The march of the checkpoint inhibitors. Nat Rev Clin Oncol. 2017;14:131–2. doi:10.1038/nrclinonc.2017.15. PMID:28218255.
   PubMed Web of Science ®Google Scholar
• Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36–49. doi:10.1016/j.ctrv.2017.05.003. PMID:28550712.
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. doi:10.1016/j.ctrv.2016.02.003. PMID:26922661.
   PubMed Web of Science ®Google Scholar
• Kumar V, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017;8:49. doi:10.3389/fphar.2017.00049. PMID:28228726.
   PubMed Web of Science ®Google Scholar
• Booth CM, Del Paggio JC. Approvals in 2016: Questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol. 2017;14:135–6. doi:10.1038/nrclinonc.2017.18. PMID:28218259.
   PubMed Web of Science ®Google Scholar
• Bethune MT, Joglekar AV. Personalized T cell-mediated cancer immunotherapy: Progress and challenges. Curr Opin Biotechnol. 2017;48:142–52. doi:10.1016/j.copbio.2017.03.024. PMID:28494274.
   PubMed Web of Science ®Google Scholar
• Capietto AH, Jhunjhunwala S, Delamarre L. Characterizing neoantigens for personalized cancer immunotherapy. Curr Opin Immunol. 2017;46:58–65. doi:10.1016/j.coi.2017.04.007. PMID:28478383.
   PubMed Web of Science ®Google Scholar
• Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17:286–301. doi:10.1038/nrc.2017.17. PMID:28338065.
   PubMed Web of Science ®Google Scholar
• Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv Drug Deliv Rev. 2017;114:33–42. doi:10.1016/j.addr.2017.04.011. PMID:28455187.
   PubMed Web of Science ®Google Scholar
• Fiori ME, Villanova L, De Maria R. Cancer stem cells: At the forefront of personalized medicine and immunotherapy. Curr Opin Pharmacol. 2017;35:1–11. doi:10.1016/j.coph.2017.04.006. PMID:28527911.
   PubMedGoogle Scholar
• Barrero MJ. Epigenetic Strategies to Boost Cancer Immunotherapies. J Mol Sci. 2017;18(6):1108. doi:10.3390/ijms18061108.
   Google Scholar
• Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, et al. Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget. 2017;8(29):48507–20. PMID:28501851.
   PubMed Web of Science ®Google Scholar
• Yuan, J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016;4:3. doi:10.1186/s40425-016-0107-3. PMID:26788324.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5:44. doi:10.1186/s40425-017-0243-4. PMID:28515944.
   PubMed Web of Science ®Google Scholar
• Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017;117:1–7. doi:10.1038/bjc.2017.136. PMID:28524159.
   PubMed Web of Science ®Google Scholar
• Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev. 2017;114:79–101. PMID:28545888.
   PubMed Web of Science ®Google Scholar
• Catani JPP, Riechelmann RP, Adjemian S, Strauss BE. Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials. Hum Vaccin Immunother. 2017;13:1109–11. doi:10.1080/21645515.2016.1269046. PMID:28059608.
   PubMed Web of Science ®Google Scholar
• Ajay Dara ATS. Clearing the Fog of Anticancer Patents from 1993–2013_ Through an In-Depth Technology Landscape & Target Analysis from Pioneer Research Institutes and Universities Worldwide. PLOS ONE. 2014;9:e103847. doi:10.1371/journal.pone.0103847. PMID:25083710.
   PubMed Web of Science ®Google Scholar
• Storz U. Intellectual property issues of immune checkpoint inhibitors. MAbs. 2016;8:10–26. doi:10.1080/19420862.2015.1107688. PMID:26466763.
   PubMed Web of Science ®Google Scholar
• Collin M. Immune checkpoint inhibitors: A patent review (2010-2015). Expert Opin Ther Pat. 2016;26:555–64. doi:10.1080/13543776.2016.1176150. PMID:27054314.
   PubMed Web of Science ®Google Scholar
• Kong X, Hu Y, Cai Z, Yang F, Zhang Q. Dendritic-cell-based technology landscape: Insights from patents and citation networks. Hum Vaccin Immunother. 2015;11:682–8. doi:10.1080/21645515.2015.1008857. PMID:25714961.
   PubMed Web of Science ®Google Scholar
• Buonaguro FM, Tornesello ML, Izzo F, Buonaguro L. Oncolytic virus therapies. Pharm Pat Anal. 2012;1:621–7. doi:10.4155/ppa.12.65. PMID:24236929.
   PubMedGoogle Scholar
• Geng X, Kong X, Hu H, Chen J, Yang F, Liang H, Chen X, Hu Y. Research and development of therapeutic mAbs: An analysis based on pipeline projects. Hum Vaccin Immunother. 2015;11:2769–76. doi:10.1080/21645515.2015.1074362. PMID:26211701.
   PubMed Web of Science ®Google Scholar
• Storz U. Antibody-drug conjugates: Intellectual property considerations. MAbs. 2015;7:989–1009. doi:10.1080/19420862.2015.1082019. PMID:26292154.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol. 1995;13:399–415. doi:10.1146/annurev.iy.13.040195.002151. PMID:7612229.
   PubMed Web of Science ®Google Scholar
• Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol. 1998;68:122–38. doi:10.1002/(SICI)1096-9098(199806)68:2<122::AID-JSO10>3.0.CO;2-4. PMID:9624043.
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Kilinc MO, Gu T, Conway TF. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune Disord Drug Targets. 2007;7:266–70. doi:10.2174/187153007782794335. PMID:18220947.
   PubMedGoogle Scholar
• Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98:298–300. doi:10.1093/jnci/djj111. PMID:16507823.
   PubMed Web of Science ®Google Scholar
• Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 2007;7:141–8. doi:10.2174/156800907780058817. PMID:17346105.
   PubMed Web of Science ®Google Scholar
• Rowan K. Oncolytic viruses move forward in clinical trials. J Natl Cancer Inst. 2010;102:590–5. doi:10.1093/jnci/djq165. PMID:20421567.
   PubMedGoogle Scholar
• Assessment of adenoviral vector safety and toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther. 2002;13:3–13. doi:10.1089/10430340152712629. PMID:11779411.
   PubMed Web of Science ®Google Scholar
• Kou Y-H, Chen C-L. Exploring the Business Opportunities in Cancer Immunotherapy (in Chinese). p. 137 (Development Center for Biotechnology; 2016.
   Google Scholar
• Squicciarini M, Dernis H, Criscuolo C. Measuring patent quality:indicators of technological and economic value. OECD Science, Technology and Industry Working Papers. 2013. doi:10.1787/5k4522wkw1r8-en
   Google Scholar
• Hall BH, Trajtenberg M. Uncovering GPTS with Patent Data NBER Working Papers No. 10901, 2004.
   Google Scholar